Research by Williams et al. [23] indicated that in the treatment of BCR-ABL1 positive B-ALL with imatinib, the presence of ARF deletion at the p14 locus encoded by the CDKN2A can affect sensitivity to imatinib, leading to drug resistance and poorer treatment outcomes. Here, CDKN2A is linked to acute lymphoblastic leukemia.